Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Block

Showing results (471-480 of 488) with videos related to

Pageof 49
Sort By:
Journal for Immunotherapy of Cancer|March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerStephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2024
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, et al.
Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.
American Journal of Hematology|June 17, 2021
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapyAntoine N Saliba, Zhuoer Xie, Alexandra S Higgins, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
JCO Oncology Advances|April 1, 2026
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark AnalysisLuigi A De Vitis, Melissa C Larson, Hunter J Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 49

Showing results (471-480 of 488) with videos related to

Sort By:
Pageof 49
Journal for Immunotherapy of Cancer|March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerStephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2024
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, et al.
Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.
American Journal of Hematology|June 17, 2021
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapyAntoine N Saliba, Zhuoer Xie, Alexandra S Higgins, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
JCO Oncology Advances|April 1, 2026
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark AnalysisLuigi A De Vitis, Melissa C Larson, Hunter J Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 49